Literature DB >> 22975466

Relation of uric acid to serum levels of high-sensitivity C-reactive protein, triglycerides, and high-density lipoprotein cholesterol and to hepatic steatosis.

Tanya Keenan1, Michael J Blaha, Khurram Nasir, Michael G Silverman, Rajesh Tota-Maharaj, Jose A M Carvalho, Raquel D Conceição, Roger S Blumenthal, Raul D Santos.   

Abstract

Increased uric acid (UA) is strongly linked to cardiovascular disease. However, the independent role of UA is still debated because it is associated with several cardiovascular risk factors including obesity and metabolic syndrome. This study assessed the association of UA with increased high-sensitivity C-reactive protein (hs-CRP), increased ratio of triglyceride to high-density lipoprotein cholesterol (TG/HDL), sonographically detected hepatic steatosis, and their clustering in the presence and absence of obesity and metabolic syndrome. We evaluated 3,518 employed subjects without clinical cardiovascular disease from November 2008 through July 2010. Prevalence of hs-CRP ≥3 mg/L was 19%, that of TG/HDL ≥3 was 44%, and that of hepatic steatosis was 43%. In multivariable logistic regression after adjusting for traditional cardiovascular risk factors and confounders, highest versus lowest UA quartile was associated with hs-CRP ≥3 mg/L (odds ratio [OR] 1.52, 95% confidence interval [CI] 1.01 to 2.28, p = 0.04), TG/HDL ≥3 (OR 3.29, 95% CI 2.36 to 4.60, p <0.001), and hepatic steatosis (OR 3.10, 95% CI 2.22 to 4.32, p <0.001) independently of obesity and metabolic syndrome. Association of UA with hs-CRP ≥3 mg/L became nonsignificant in analyses stratified by obesity. Ascending UA quartiles compared to the lowest UA quartile demonstrated a graded increase in the odds of having 2 or 3 of these risk conditions and a successive decrease in the odds of having none. In conclusion, high UA levels were associated with increased TG/HDL and hepatic steatosis independently of metabolic syndrome and obesity and with increased hs-CRP independently of metabolic syndrome.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22975466      PMCID: PMC3766845          DOI: 10.1016/j.amjcard.2012.08.012

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  26 in total

1.  Uric acid: a danger signal from the RNA world that may have a role in the epidemic of obesity, metabolic syndrome, and cardiorenal disease: evolutionary considerations.

Authors:  Richard J Johnson; Miguel A Lanaspa; Eric A Gaucher
Journal:  Semin Nephrol       Date:  2011-09       Impact factor: 5.299

2.  The metabolic syndrome--a new worldwide definition.

Authors:  K George M M Alberti; Paul Zimmet; Jonathan Shaw
Journal:  Lancet       Date:  2005 Sep 24-30       Impact factor: 79.321

3.  Increased oxidative stress in obesity and its impact on metabolic syndrome.

Authors:  Shigetada Furukawa; Takuya Fujita; Michio Shimabukuro; Masanori Iwaki; Yukio Yamada; Yoshimitsu Nakajima; Osamu Nakayama; Makoto Makishima; Morihiro Matsuda; Iichiro Shimomura
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

4.  A causal role for uric acid in fructose-induced metabolic syndrome.

Authors:  Takahiko Nakagawa; Hanbo Hu; Sergey Zharikov; Katherine R Tuttle; Robert A Short; Olena Glushakova; Xiaosen Ouyang; Daniel I Feig; Edward R Block; Jaime Herrera-Acosta; Jawaharlal M Patel; Richard J Johnson
Journal:  Am J Physiol Renal Physiol       Date:  2005-10-18

5.  Reactive oxygen species facilitate adipocyte differentiation by accelerating mitotic clonal expansion.

Authors:  Haemi Lee; Yoo Jeong Lee; Hyeonjin Choi; Eun Hee Ko; Jae-Woo Kim
Journal:  J Biol Chem       Date:  2009-02-23       Impact factor: 5.157

Review 6.  Molecular mediators of hepatic steatosis and liver injury.

Authors:  Jeffrey D Browning; Jay D Horton
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

Review 7.  Uric acid: A marker of increased cardiovascular risk.

Authors:  Ana C M Gagliardi; Marcio H Miname; Raul D Santos
Journal:  Atherosclerosis       Date:  2008-05-21       Impact factor: 5.162

8.  AUDIT-C as a brief screen for alcohol misuse in primary care.

Authors:  Katharine A Bradley; Anna F DeBenedetti; Robert J Volk; Emily C Williams; Danielle Frank; Daniel R Kivlahan
Journal:  Alcohol Clin Exp Res       Date:  2007-04-19       Impact factor: 3.455

9.  Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome.

Authors:  Laura G Sánchez-Lozada; Edilia Tapia; Pablo Bautista-García; Virgilia Soto; Carmen Avila-Casado; Iliana P Vega-Campos; Takahiko Nakagawa; Lin Zhao; Martha Franco; Richard J Johnson
Journal:  Am J Physiol Renal Physiol       Date:  2008-01-23

Review 10.  Uric acid and cardiovascular risk.

Authors:  Daniel I Feig; Duk-Hee Kang; Richard J Johnson
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245

View more
  23 in total

1.  Short duration of sleep is associated with elevated high-sensitivity C-reactive protein level in Taiwanese adults: a cross-sectional study.

Authors:  Jui-Kun Chiang
Journal:  J Clin Sleep Med       Date:  2014-07-15       Impact factor: 4.062

2.  Evaluation of the causal effects of blood lipid levels on gout with summary level GWAS data: two-sample Mendelian randomization and mediation analysis.

Authors:  Xinghao Yu; Ting Wang; Shuiping Huang; Ping Zeng
Journal:  J Hum Genet       Date:  2020-10-25       Impact factor: 3.172

3.  Evaluation of Association of Hyperuricaemia with Metabolic Syndrome and Insulin Resistance.

Authors:  Naveen Reddy Avula; Damodar Shenoy
Journal:  J Clin Diagn Res       Date:  2016-12-01

4.  Prediction of Individual Basal Rate Profiles From Patient Characteristics in Type 1 Diabetes on Insulin Pump Therapy.

Authors:  Michael A Nauck; Melanie Kahle-Stephan; Anna M Lindmeyer; Sina Wenzel; Juris J Meier
Journal:  J Diabetes Sci Technol       Date:  2020-11-30

Review 5.  Metabolic Dysfunction in the Regulation of the NLRP3 Inflammasome Activation: A Potential Target for Diabetic Nephropathy.

Authors:  Wenli Zhao; Le Zhou; Petr Novák; Xian Shi; Chuang Biao Lin; Xiao Zhu; Kai Yin
Journal:  J Diabetes Res       Date:  2022-06-09       Impact factor: 4.061

6.  Mendelian randomization provides no evidence for a causal role of serum urate in increasing serum triglyceride levels.

Authors:  Humaira Rasheed; Kim Hughes; Tanya J Flynn; Tony R Merriman
Journal:  Circ Cardiovasc Genet       Date:  2014-09-23

Review 7.  Hyperuricemia and nonalcoholic fatty liver disease: from bedside to bench and back.

Authors:  Chengfu Xu
Journal:  Hepatol Int       Date:  2015-12-15       Impact factor: 6.047

8.  Elevated triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio increased risk of hyperuricemia: a 4-year cohort study in China.

Authors:  Xin-Yao Liu; Qiao-Yu Wu; Zhi-Heng Chen; Guang-Yu Yan; Yao Lu; Hai-Jiang Dai; Ying Li; Ping-Ting Yang; Hong Yuan
Journal:  Endocrine       Date:  2020-01-15       Impact factor: 3.633

9.  Association of uric acid with metabolic syndrome in men, premenopausal women and postmenopausal women.

Authors:  Yongqiang Li; Shanying Chen; Xiaofei Shao; Jia Guo; Xinyu Liu; Aiqun Liu; Ying Zhang; Honglei Wang; Bin Li; Kangping Deng; Qin Liu; Harry Holthöfer; Hequn Zou
Journal:  Int J Environ Res Public Health       Date:  2014-03-10       Impact factor: 3.390

10.  Relationship between hyperuricemia and lipid profiles in US adults.

Authors:  Tao-Chun Peng; Chung-Ching Wang; Tung-Wei Kao; James Yi-Hsin Chan; Ya-Hui Yang; Yaw-Wen Chang; Wei-Liang Chen
Journal:  Biomed Res Int       Date:  2015-01-05       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.